Expanded access to daraxonrasib for advanced pancreatic cancer
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This program gives early access to an experimental pill called daraxonrasib for people whose pancreatic cancer has spread and has not responded to previous chemotherapy. It is not a regular clinical trial but a way to try the drug if no other options are available.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and agree to participate.
- You have stage 4 pancreatic cancer that has gotten worse after at least one treatment.
- You have had chemo with a drug like gemcitabine or 5-FU.
- Your cancer has not spread to your brain.
- You can swallow pills and do not have major stomach or bowel problems that would stop you from absorbing the medicine.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new targeted therapy (daraxonrasib) combined with standard chemotherapy as the first treatment for people whose pancreatic cancer has spread. The goal is to see if this combination can help shrink or control the cancer better than chemotherapy alone.
This trial tests an experimental daily pill, daraxonrasib, in people with pancreatic cancer that has been surgically removed. It’s for those who also had chemotherapy and have a specific DNA change called a RAS mutation. The goal is to see if the pill helps prevent the cancer from coming back.
This trial tests a new combination treatment for pancreatic cancer that has spread or cannot be removed with surgery. The goal is to see if the combination can help control the cancer and is safe.
This trial tests whether adding a new drug called zoldonrasib to standard chemotherapy works better than chemotherapy alone for pancreatic cancer that has spread and has a specific KRAS G12D mutation. The goal is to see if this combination helps patients live longer and control their cancer better.
This trial tests a new drug called RMC-5127 for people with advanced solid tumors that have a specific KRAS G12V mutation. The study aims to see if this targeted therapy can help when other treatments have stopped working or caused side effects.
This trial compares an experimental drug called DN022150 to standard chemotherapy for people with advanced pancreatic cancer that has a specific genetic change called KRAS G12D. It is for those who have already tried other treatments.
Hear when a new PDAC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.